Related Experiment Video

Updated: Feb 28, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.2K

Back to life with checkpoint inhibitors in Hodgkin lymphoma

Reyad Dada1,2, Jamal Zekri1,2

  • 11 King Faisal Specialist Hospital and Research Center, Jeddah, Kingdom of Saudi Arabia.

Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|June 10, 2017
PubMed

Insights

Nivolumab, an immunotherapy, effectively treats advanced Hodgkin lymphoma resistant to other therapies. This programmed cell death 1 inhibitor offers hope by reviving the immune system response against cancer.

Area of Science:

  • Oncology
  • Immunotherapy
  • Hematology

Background:

  • Cancer immune evasion involves Programmed Death Ligand-1 (PD-L1) binding to the Programmed Cell Death 1 (PD-1) receptor on T cells, suppressing immune responses.
  • Nivolumab is a novel antibody targeting the PD-1 receptor, designed to counteract immune tolerance induced by cancer.

Observation:

  • A 30-year-old male with stage IVB Hodgkin lymphoma achieved a major response after four cycles of Nivolumab.
  • This patient had previously undergone nine lines of treatment, including high-dose chemotherapy, autologous stem cell transplantation, and brentuximab vedotin, without success.

Findings:

  • Single-agent Nivolumab demonstrated significant clinical efficacy in a heavily pre-treated Hodgkin lymphoma patient.
  • The treatment was well-tolerated, leading to a major response and improved quality of life.

Implications:

  • Nivolumab represents a promising immunotherapy option for refractory Hodgkin lymphoma, reviving anti-cancer immune responses.
  • Further clinical studies are warranted to establish Nivolumab's efficacy in a larger patient cohort for Hodgkin lymphoma.
Keywords:
Checkpoint inhibitorsHodgkin lymphomaPD-1 inhibitorsnivolumabrefractory/relapsed Hodgkin lymphoma

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.8K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.6K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K